drugset
drugset / Trial / NCT01527539

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

NCT01527539 ↗

Phase 3 Completed 25 enrolled Novo Nordisk A/S
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial is conducted in North America. The aim of this trial is asses the long term safety and efficacy of biphasic insulin aspart 30 in Canadian subjects with type 2 diabetes who had participated in the BIAsp-1237 trial.

Timeline

Start
2001-11-23
Primary completion
2004-10-12
Completion
2004-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject biphasic insulin aspart 30 Protein / enzyme biologic — Subcutaneous

Indications

type 2 diabetes mellitus